AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04028258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mixture of fibers + Placebo
Description: Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)
Study NCT04028258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo + Mixture of fibers
Description: Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
Study NCT02648360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
Study NCT02663193 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
Study NCT03135860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide 30mcg/kg IBW/hr
Description: Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
Study NCT00737243 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 15 mg/kg IV infusion Day 1
Study NCT00737243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg PO
Study NCT00737243 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150 mg PO
Study NCT00737243 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment determined by physician
Description: Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
Study NCT00677131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading the package insert of the drug
Description: package insert of the drug
Study NCT03992495 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: All participants will be exposed to aerobic/strengthening exercises
Study NCT00677131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading the education information provided by the Pharmacy of NTUH
Description: education information
Study NCT01702298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/simvastatin 40 mg FDC
Description: Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
Study NCT01702298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
Study NCT02504619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CordIn
Description: CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
Study NCT01809964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401
Study NCT01809964 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT02824367 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Completion of scales evaluation
Description: Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
Study NCT01376141 — intervention group
Intervention type: DRUG
Intervention: Sumatriptan
Study NCT03093792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT03093792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Heart Association plus exercise
Study NCT03093792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Curves Complete - I plus exercise
Study NCT03093792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Curves Complete - II plus exercise
Study NCT02192034 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Navigation
Study NCT02192034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Study NCT02299635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 10 mg, twice a day.
Study NCT02299635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 50 mg, twice a day
Study NCT02299635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: Tablet, 100 mg, twice a day
Study NCT04147416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486 0.1-0.2 /0.3 mg / kg group
Description: Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
Study NCT04147416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 0.5-1.0/1.5 mg/kg group
Description: Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
Study NCT03278028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution
Description: A-101 Topical Solution
Study NCT03278028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101 Vehicle Solution
Description: A-101 Vehicle Solution
Study NCT06390891 — intervention group
Intervention type: OTHER
Intervention: Persons with pancreatic resection in a hospital with at least 50 pancreatic resections annually (observational),
Description: Persons that have undergone a pancreatic resection at a hospital with at least 50 pancreatic resections annually (observational)
Study NCT06390891 — intervention group
Intervention type: OTHER
Intervention: Persons with pancreatic resection in a hospital not performing at least 50 pancreatic resections annually (observational),
Description: Persons that have undergone a pancreatic resection at a hospital with not at least 50 pancreatic resections annually (observational)
Study NCT04374708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: fMRI: body morph test and neurocognitive testing
Study NCT03407924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
Study NCT02868216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: anger management training
Study NCT01167426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate 20 mg/0.5 mL
Description: 20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
Study NCT01167426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer acetate 20 mg/0.5 mL
Description: 20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
Study NCT01930019 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)
Study NCT01930019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)
Study NCT02993471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Administered orally
Study NCT02993471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT02638415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG-guided therapy
Description: Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails.
Study NCT03837821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 200 mg oral, every 12 hours
Study NCT04041388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conebeam CT
Description: medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
Study NCT01433458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030A
Description: RLX030 is administered as a continuous 24 hour infusion
Study NCT01433458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLX030A
Description: RLX030 is administered as a continuous 24 hour infusion
Study NCT03331159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoBone
Description: Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix
Study NCT03331159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Homologous Bone
Description: Cage was filled with homologous bone
Study NCT01749358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Description: A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
Study NCT01749358 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active Monitoring
Description: This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
Study NCT03798379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
Study NCT04473716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
Study NCT04473716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxcel
Description: Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
Study NCT04473716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
Study NCT04473716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
Study NCT04473716 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy/chemoradiotherapy
Description: Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
Study NCT03899649 — intervention group
Intervention type: DRUG
Intervention: SOC
Description: Standard of Care treatment
Study NCT03899649 — intervention group
Intervention type: DEVICE
Intervention: NanoKnife System
Description: Irreversible Electroporation
Study NCT04451928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum sample analysis
Description: Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
Study NCT02638519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Proton fMRI
Description: Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
Study NCT02638519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarized Xenon-129 fMRI
Description: HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
Study NCT02638519 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized Xenon-129
Description: Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Study NCT02638519 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 1H-129Xe Dual-Tuned Quadrature Head Coil
Description: A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
Study NCT02638415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: routine therapy
Description: Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
Study NCT00677131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral education provided by the pharmacist
Description: Oral education provided by the pharmacist
Study NCT00956969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger Awareness and Expression
Description: Teaches patients to recognize, experience, and express emotions
Study NCT02638415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
Study NCT00956969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Teaches patients relaxation training
Study NCT00456248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infergen and ribavirin
Description: Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
Study NCT02769104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole (Aromatase Inhibitors)
Description: Letrozole (Aromatase Inhibitors) for 5 years
Study NCT02769104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC*4-T*4
Description: CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
Study NCT02769104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC*4-T*4
Description: CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
Study NCT01779960 — intervention group
Intervention type: OTHER
Intervention: Londrina
Description: Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
Study NCT00456248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infergen and ribavirin
Description: Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
Study NCT02638415 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carvedilol
Description: Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
Study NCT04531488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Powered Mobility Training Simulator
Description: Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
Study NCT04531488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training with Powered Wheel Chair
Description: Training with Powered Wheel Chair
Study NCT00604006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg tablets (placed in capsules for blinding) once daily.
Study NCT00604006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (lactose in capsules for blinding) once daily
Study NCT03985072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andes-1537 for Injection
Description: Andes-1537 administered subcutaneously five days per week.
Study NCT02882048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NADA Protocol
Description: NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
Study NCT02882048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication management
Description: Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
Study NCT04472364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoPill Acute ®
Description: Capsule positive: Endoscopy endoscopy will be performed within 12 hours. Capsule negative: Endoscopy will be performed after 48 to 96 hours.
Study NCT04747483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extension Oriented Treatment Approach
Description: The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland.
Study NCT02882048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication management
Description: Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
Study NCT02410538 — intervention group
Intervention type: OTHER
Intervention: list of FAQ
Study NCT00973141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
Study NCT00973141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
Study NCT04747483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EOTA+ Traction
Description: Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks.
Study NCT04022174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate dosage training of action Observation and Motor imagery
Description: Motor imagery and action observation of orofacial exercises with moderate dosage
Study NCT04022174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive dosage training of action observation and motor imagery
Description: Motor imagery and action observation of the orofacial exercises with intensive dosage
Study NCT01779960 — intervention group
Intervention type: OTHER
Intervention: Leuven
Description: Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
Study NCT04022174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intensive dosage orofacial exercises
Description: Orofacial exercises with high intensity
Study NCT04022174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate dosage orofacial exercises
Description: Orofacial exercises with moderate intensity